26 March 2019 - Louisiana has picked a pharmaceutical company for its unusual plan to broaden access to hepatitis C drugs for Medicaid patients and prisoners through a Netflix-style subscription model, the state health department announced Tuesday.

Gilead Sciences subsidiary Asegua Therapeutics won the contract, selected from three companies that sought to partner with the state. 

Louisiana will pay a fee to the drug manufacturer for unlimited access to its hepatitis C medication, a generic version of Epclusa, for five years.

Read San Francisco Chronicle article